Clinical studies with clopidogrel or prasugrel show that while increased inhibition of P2Y 12 and platelet function improves efficacy, bleeding is also increased.
Introduction
The thienopyridine clopidogrel has emerged as a primary drug for the treatment and the prevention of arterial thrombosis in patients with cardiovascular disease (1996; Mehta et al., 2001; Yusuf et al., 2001) . The pharmacologic activity of clopidogrel requires metabolism by cytochrome P450 to generate a highly unstable active metabolite to inhibit platelet function (Savi et al., 1992; Savi et al., 2000) . Although the pharmacologic target of this drug was not known upon approval, work in our laboratory using an expression cloning strategy identified the target as P2Y 12 , a Gi-coupled receptor on platelets (Foster et al., 2001; Hollopeter et al., 2001) . In a subsequent study, we generated P2Y 12 -/-mice and showed that P2Y 12 functions in arterial thrombosis by maintaining thrombus stability (Andre et al., 2003a) . While increased doses of clopidogrel provide increased inhibition of P2Y 12 and increased efficacy, this is invariably associated with increased bleeding (Mehta and Van de Werf, 2009) . That this is a cause and effect relationship is supported by recent data (Rehmel et al., 2006) showing that prasugrel, another thienopyridine that also generates an active metabolite to irreversibly inhibit P2Y 12 and platelet function, provides increased efficacy and increased bleeding (Wiviott et al., 2007) .
Although it is commonly anticipated that bleeding propensity will parallel the antiaggregatory effects of a P2Y 12 antagonist, there have been multiple reports of excessive bleeding associated with thienopyridines. For example, studies performed in rabbits suggest that unexplained bleeding occurs above levels of JPET#178574 clopidogrel required to provide complete inhibition of platelet aggregation (Wong et al., 2009) . Particularly, high doses of clopidogrel providing limited incremental benefits in preventing arterial thrombosis have been associated with disproportionate levels of bleeding in both rabbits and rats (Schumacher et al., 2007; Wong et al., 2007) . Similar discrepancies have been reported in humans, with CYP2C19*2 carriers having higher rate of thrombotic events but similar rates of bleeding as non-carriers (Mega et al., 2009) . Also, marked bleeding has been reported in the TRITON-TIMI 38 trial with prasugrel (Wiviott et al., 2007) . In contrast, reversible antagonism of P2Y 12 has been proposed to offer a potent and safer alternative to thienopyridine agents (Storey et al., 2002; Husted et al., 2006; Wang et al., 2007; van Giezen et al., 2009 ) although a potential off-P2Y 12 effect on platelet function has also been reported for cangrelor (Srinivasan et al., 2009 ).
Thus, while the antithrombotic activities of the thienopyridines can be directly linked to the inhibition of P2Y 12 , platelet function and thrombosis, it is unknown whether the bleeding consequences of the thienopyridines are entirely P2Y 12 -dependent.
The present study was designed to establish whether bleeding induced by the thienopyridines is entirely P2Y 12 -dependent. We found that while dosing of mice with the three agents had no effects on coagulation parameters, achieved the same inhibition of arterial thrombosis and the same levels of anti-aggregatory activities in vitro as in P2Y 12 -/-mice, both thienopyridines caused more bleeding in two primary hemostasis models than occurred in P2Y 12 -/-mice or in WT JPET#178574 6 animals treated with a reversible P2Y 12 antagonist (elinogrel). Furthermore, dosing of P2Y 12 -/-mice with clopidogrel or prasugrel further increased bleeding.
Additional data using a mouse model of vasoconstriction indicated that one component of bleeding induced by thienopyridines is caused by inhibition of a target other than P2Y 12 at the vessel wall, and that unlike the effect on platelet P2Y 12 receptors, is of a reversible nature.
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Methods
Drugs
Clopidogrel was from Sequoia Research Products Ltd. (United Kingdom).
Prasugrel was from Albany Molecular Research (USA). Elinogrel (Ueno et al.
2010) was from Portola Pharmaceuticals (USA).
Animals
C57/BL6J mice (Charles River) were used for determination of antithrombotic activities of clopidogrel and prasugrel, determination of their effects on primary hemostasis and ex vivo platelet aggregation. P2Y 12 knockout mice (on a pure C57/BL6J background (>10 times backcrossed)) were used for thrombosis and hemostasis studies. All experiments were performed by investigators blinded to the different treatments. All procedures conformed to institutional guidelines and to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, Md).
Thrombosis study
Thrombosis on mouse mesenteric arteries (1000-1300 s -1
) was performed and recorded as previously described with minor modifications (Andre et al., 2003b) .
Platelets were labeled in situ using rhodamine 6G (0.2 mg/mL) administered through the tail vein 10 minutes before visualization of the arteries. Vessel-wall injury was induced by a 1x1-mm filter paper saturated with a 10% FeCl 3 solution.
After 5 minutes, the filter paper was removed and mesenteric arteries rinsed with JPET#178574 warmed saline (37°C). Platelet-vessel wall interactions were recorded for 40 additional minutes or until full occlusion occurred and lasted for more than 40 seconds. C57Bl6J mice were orally gavaged 48, 24 and 2 hours prior to injury with vehicle control (0.5% methylcellulose), clopidogrel (0.25, 1.5, 15 and 50 mg/kg) or prasugrel (0.1, 0.3, 1, 3, 10 mg/kg), or 2 hours (on the basis of elinogrel murine pharmacokinetic profile, see Supplemental Figure 1A ) prior to injury with elinogrel (0.83, 2.5, 7.5, 20 and 60 mg/kg,).
Video analysis
Thrombosis was analyzed in real time using Simple PCI software (Andre et al., 2003a) . The fluorescence intensity was recorded at a rate of 2 Hz for 40 minutes and plotted over time. Time to occlusion and time for appearance of first thrombus were analyzed.
Elinogrel plasma concentration determination
Plasma samples were analyzed for elinogrel concentration using a liquid chromatography tandem mass spectrometry (LC/MS/MS). In brief, whole blood was collected on trisodium citrate (1:9 vol) and platelet poor plasma prepared. (PRT061200) product ion (internal standard) in positive ion mode. The analytical range was 2.00 to 5000 ng/mL.
Ex vivo platelet aggregation study and coagulation assays
In a separate set of experiments, C57Bl6J mice were orally gavaged for 3 consecutive days with 0.5% methylcellulose (BID, in 100 μL), clopidogrel (QD, 50 mg/kg in 100 μL), prasugrel (QD, 10 mg/kg in 100 μL) or elinogrel (BID, 60 mg/kg in 100 μL). The last dose was given 3 hours prior to blood collection.
Measurements were performed using a 4-channel Chronolog lumiaggregometer using Aggrolink software. Blood samples (0.6 ml per anesthetized mouse) were obtained via intracardiac puncture (on 3.2% trisodium citrate, 1vol TSC : 9 vol of blood), centrifuged at 200xg for 10 minutes and platelet rich plasma (PRP) -/-mice were also orally gavaged (using the same regimen) with maximal doses of clopidogrel, prasugrel, elinogrel and vehicle control.
Tail blood loss measurement
Blood loss was assessed when collection of blood for bleed time determination had concluded. To measure blood loss volume, any blood collected as described above following tail transection was frozen at -80 °C overnight. After thawing the following day, 10 ml of deionized water was added to further induce hemolysis. Aliquots of each sample were analyzed via spectrophotometry 
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The in vivo primary hemostasis model was performed via micropuncture (using a 27 G needle) of mesenteric veins according to the model developed by van Gestel and colleagues (van Gestel et al., 2007) . Briefly, 3-4 week-old anesthetized P2Y 12 -/-and WT mice previously orally gavaged (48, 24 and 2 hours prior to injury) with either 0.5% methycellulose, clopidogrel (50 mg/kg), prasugrel (10 mg/kg) or elinogrel (60 mg/kg 2 hours prior to micropuncture) were injected with R6G (0.2 mg/ml) to fluorescently label platelets in situ. Using videomicroscopy, a 27G needle (mounted on a 1 ml syringe) was pressed on the mesenteric vein to induce rupture of the vascular wall. Bleeding time and platelet recruitment at site of micropuncture were then recorded for 20 minutes and quantified in real time using intravital microscopy.
In vivo vasoconstriction studies in mesenteric veins
Mesenteric veins (100-190 μm diameter) from 3 to 4 week-old anesthetized P2Y 12 -/-or WT mice were observed using brightfield inverted microscopy. In a first set of experiments, mice were orally gavaged with 0.5% methylcellulose 
Statistical analysis
Analysis was performed using the standard Student's t test. Statistical analysis of the blood loss study comparing doses of clopidogrel, prasugrel and elinogrel to naïve or 0.5% methylcellulose P2Y 12 knockout mice was performed using oneway ANOVA (Bonferroni's multiple comparison test). All values are expressed as mean ± SEM unless otherwise specified.
This article has not been copyedited and formatted. The final version may differ from this version. (destabilization of growing arterial thrombi preventing vascular occlusion; Figure   1A ). Although these maximal doses totally inhibited occlusion, subtle differences were observed compared with P2Y 12 -/-mice as maximal clopidogrel dose did not reach similar levels of inhibition achieved by P2Y 12 gene targeting on the initial rate of thrombus growth (p<0.0001 vs P2Y 12 -/-for time for appearance of first thrombus; Figure 1B ). In addition, while preventing vascular occlusion, there were more fluorescent platelets deposited throughout the 40 min observation period with the maximal dose of clopidogrel ( Figure 1C ). In contrast, the maximal doses of prasugrel and elinogrel had a thrombosis phenotype identical to that of Figure 5A ), despite the fact that they were not able to prevent vascular occlusion ( Figure 1A ), indicating that some levels of bleeding could not be accounted for by the sole anti-platelet effect. Data obtained with thienopyridines were in sharp contrast with the volume of blood loss associated with elinogrel which in all cases, were less than the blood loss observed in P2Y 12 -/-mice.
Clopidogrel and prasugrel increase blood loss when dosed in P2Y 12 -/-mice
Since the maximal doses of clopidogrel and prasugrel extended blood loss beyond the level of the P2Y 12 -/-mouse, we next asked whether they would affect 
Clopidogrel and prasugrel block vasoconstriction in mesenteric veins
While studying platelet deposition in the micropuncture model, we noticed that the mesenteric veins of thienopyridine-treated mice had a reduced constriction in response to mechanical injury. To investigate further a potential effect of these pharmacological agents on the vascular tone, we next studied the response of clinical benefit, accompanied by significantly more bleeding. The observations described in the present study suggest that some of the additional bleeding observed with prasugrel may be due to off-target activity.
This article has not been copyedited and formatted. The final version may differ from this version. with the use of thienopyridines. C) Effects of maximal doses of clopidogrel (C., n = 10), prasugrel (P., n = 8), elinogrel (E., n = 10) and methylcellulose (MC., n = 9) on blood loss measurement in P2Y 12 -/-mice (n = 19). This article has not been copyedited and formatted. The final version may differ from this version.
